This technology includes a microscopy technique that produces super-resolution images from diffraction-limited images obtained from a line scanning confocal microscope. First, the operation of the confocal microscope is modified so that images with sparse line excitation are recorded. Second, these images are processed to increase resolution in one dimension. Third, by taking a series of such super-resolved images from a given sample type, a neural network may be trained to produce images with 1D super-resolution from new diffraction-limited images.

This technology includes synthesis of S-2-((S)-3-(4-chlorophenyl)-N'-((4-chlorophenyl) sulfonyl)-4-phenyl-4,5-dihydro-1 H-pyrazole-1-carboximidamido)- 3-(methyld3) butanamide-d5, octadeuterated JD5037 for possible use in clinical Absorption, Distribution, Metabolism, and Excretion (ADME) studies for drug discovery studies.

This technology includes novel compounds which can be expected to selectively target the 5HT6 receptor, which is implicated in CNS-related diseases. In particular 5HT6 antagonism has been implicated in cognitive impairment, AD/PD and drug abuse/alcohol abuse related disorders. 5HT6 compounds have also shown to reduce appetite and induce weight loss. As such, compounds that can selectively antagonize 5HT6 along with an additional signaling pathway implicated in such diseases like inducible nitric oxide synthase (iNOS) may be valuable for such CNS mediated diseases.

This technology includes a blood flow imaging method that allows for a higher density of smaller particles to be detected. Current imaging methods that are based on Doppler measurements are limited by the discontinuity in the capillary flow in the space between red blood cells. The core technology is to use a scattering agent to enhance capillary flow or microcirculation. This technology has been tested for optical coherence Doppler tomography, but can be expended to any Doppler based flow imaging techniques such as laser speckle imaging.

This technology includes a combination of protein biomarkers and clinical risk factors to be used as an In Vitro Diagnostic Multivariate Index Assay (IVDMIA) that can improve the identification of individuals at high risk for atherosclerotic cardiovascular disease (ASCVD) and myocardial infarction (MI). Incorporation of novel protein biomarkers of ASCVD risk into risk assessment algorithms may improve their ability to identify individuals at high risk for ASCVD.